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In this issue of the Journal, Blaxall et al. (1) report
broad-spectrum measurements of messenger ribonucleic
acid (mRNA) abundance using microarray technology in
ribonucleic acid (RNA) extracted from end-stage human
left ventricles at the time of left ventricular assist device
(LVAD) insertion and then removal two to four months
later. No left ventricular (LV) functional or dimensional
changes were made in this study, but this duration of
LVAD support has been shown to produce varying degrees
of improvement in chamber contractile function (2) and
remodeling (2,3). Although the majority of these changes
may result from unloading inasmuch as they are present at
the time of acute implantation (4), LVAD treatment in
end-stage cardiomyopathy has been shown to improve
isolated tissue (5) and cardiac myocyte function (6) and
reduce excessive cell lengthening (7). At the gene expression
level mRNA measurements of selected and limited numbers
of genes have demonstrated improvement towards normal
in some failure-associated alterations (5,8–11), but many
abnormalities are not improved by mechanical unloading
(11).
See page 1096
The report by Blaxall et al. (1) is the first report of the
application of gene chip technology to measure broad-based
gene expression in the setting of LVAD-related effects on
the end-stage failing heart. These authors (1) used the
Affymetrix GeneChip HuGeneFL Array (Santa Clara,
California), which contains 6,800 c-deoxyribonucleic acid
sequences corresponding to known human genes. That is, of
the 35,000 genes in the human genome, the mRNA
expression of around 20% of them was measured. As would
be expected, this approach generates a very large amount of
data that needs to be vetted, winnowed, and interpreted in
some meaningful way. In order to deal with these situations,
an entire subspecialty, bioinformatics, has developed, which
is basically a hybrid between computational biostatistics and
molecular biology.
To ascribe any credence to the reported findings, the first
question to be asked would be, for RNA extracted from
human hearts, how good is this technology in mRNA
quantitation? Direct comparison of GeneChip and quanti-
tative reverse transcription-polymerase chain reaction mea-
surements performed by at least two laboratories indicates
that the answer is, “quite good” (12,13). In addition, the
microarray-derived data of Blaxall et al. (1) found several
changes previously reported by more quantitative tech-
niques. The next question might be, given the large number
of measurements, how does one know whether the observed
changes are biologic or stochastic? After all, at the usual 5%
setting for type I statistical error one would expect 340
changes to be randomly significantly different, compared
with the 530 changes reported by the authors (1). Which of
these 530 changes are a real manifestation of LVAD
treatment, and which are simply statistical phenomena of
large numbers? There are multiple potential solutions to this
problem, which include requiring a higher level of signifi-
cance for measured changes, requiring same-direction
changes in most or even all examined subjects, and investi-
gating large numbers of subjects/starting material. Blaxall et
al. (1) first used a form of pattern analysis performed in
multiple dimensions, and then performed standard paired-t
analysis for fold changes calculated by the Affymetrix
algorithm. Although it can be reasonably concluded that
patterns of gene expression were truly different in the six
subjects before and after LVAD placement, the conclusion
of distinct changes in gene expression must be verified by
more quantitative and targeted means. Nevertheless, the
strength of the microarray methodology is that it allows for
the detection of changes in broad categories of gene expres-
sion, as compared to precisely measuring changes in mRNA
abundance of individual genes. In other words, with this
technology, precision is sacrificed for the ability to broadly
assess changes in a less quantitative way. So the answer to
the second question is that the Blaxall et al. (1) data are
probably meaningful in terms of categorical patterns and for
individual changes previously reported by more quantitative
mRNA measurements, but other changes are only hypoth-
esis generating.
Finally, one should ask, what are the study design
limitations? In this case there are several. First, no LV
phenotypic measurements such as function or dimensions
were made, and so it is not possible to ascribe molecular
effects to reverse remodeling/improved function versus me-
chanical unloading. To this point, the majority of changes
by category were in the metabolic class (1), consistent with
a primary effect of mechanical unloading, because in the
intact dilated cardiomyopathy heart exhibiting improve-
ment in phenotype without alteration in loading conditions,
the majority of microarray-determined gene expression
changes are in other categories (14). Second, the authors
found that the three patients with ischemic cardiomyopathy
had fewer changes than the three patients with nonischemic
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dilated cardiomyopathy, a finding that could be explained by
etiology or, more likely, by less severe LV dysfunction in the
viable myocardium taken from patients with ischemic eti-
ology. Regional contractile function measurements might
have supported one interpretation over the other. Third, the
number of subjects investigated is small, particularly when
subdivided by etiology. In other words, caution should be
exercised in interpreting specific findings in this study.
Nevertheless the report of Blaxall et al. (1) demonstrates
that commercially available microarray technology can be
employed in studies of modification of myocardial pheno-
type via LVAD. This study (1) sets the stage for more
definitive investigations that should provide major insights
into the molecular effects of this form of therapy and for the
molecular basis of myocardial failure and remodeling, as
mechanical unloading effects are distinguished from true
phenotypic improvement.
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